19th January 2016, SomnoMed Limited
(ASX:SOM) announced total revenues generated from the sale of SomnoDent® devices for the first six months of the financial year 2015/16 increased by 30.3%, compared to the previous year, to $18.05 million (unaudited). Strong direct sales for Q2 in the US and Europe resulted in quarterly MAS device revenues of $9.8 million (unaudited), which were 27.2% higher than in the previous year.
Non device revenues including managed dental service fees, cleaning tablets and repair service fees amounted to $3.29 million, bringing total revenues for the half year to December to $21.3 million (+27%).
The main features of the first half of the financial year were the excellent performance of US direct sales, solid growth in the European markets and growing acceptance for all our new products.
For further information please download PDF attached:
